Niagen Bioscience (NASDAQ:NAGE – Get Free Report) and ODDITY Tech (NASDAQ:ODD – Get Free Report) are both small-cap consumer staples companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, institutional ownership, dividends and risk.
Valuation & Earnings
This table compares Niagen Bioscience and ODDITY Tech”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Niagen Bioscience | $129.42 million | 1.13 | $17.38 million | $0.12 | 15.33 |
| ODDITY Tech | $809.84 million | 0.97 | $110.75 million | $0.19 | 71.68 |
ODDITY Tech has higher revenue and earnings than Niagen Bioscience. Niagen Bioscience is trading at a lower price-to-earnings ratio than ODDITY Tech, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
This is a summary of recent ratings and recommmendations for Niagen Bioscience and ODDITY Tech, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Niagen Bioscience | 0 | 1 | 4 | 1 | 3.00 |
| ODDITY Tech | 3 | 11 | 0 | 0 | 1.79 |
Niagen Bioscience currently has a consensus price target of $8.50, indicating a potential upside of 361.96%. ODDITY Tech has a consensus price target of $18.28, indicating a potential upside of 34.20%. Given Niagen Bioscience’s stronger consensus rating and higher probable upside, research analysts clearly believe Niagen Bioscience is more favorable than ODDITY Tech.
Profitability
This table compares Niagen Bioscience and ODDITY Tech’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Niagen Bioscience | 8.37% | 10.18% | 7.57% |
| ODDITY Tech | 1.27% | 0.66% | 0.19% |
Risk and Volatility
Niagen Bioscience has a beta of 2.12, indicating that its stock price is 112% more volatile than the S&P 500. Comparatively, ODDITY Tech has a beta of 2.14, indicating that its stock price is 114% more volatile than the S&P 500.
Insider & Institutional Ownership
15.4% of Niagen Bioscience shares are held by institutional investors. Comparatively, 35.9% of ODDITY Tech shares are held by institutional investors. 10.0% of Niagen Bioscience shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Summary
Niagen Bioscience beats ODDITY Tech on 9 of the 15 factors compared between the two stocks.
About Niagen Bioscience
Niagen Bioscience, Inc. develops and markets products based on nicotinamide riboside (NR), a form of vitamin B3 studied for its role in supporting the body’s production of NAD+. Its offerings include Tru Niagen, a consumer dietary supplement, and Niagen, a branded NR ingredient supplied to other businesses. The company also conducts and supports research on NR, NAD+ and healthy aging. It was formerly known as ChromaDex Corporation and adopted the Niagen Bioscience name in 2025. Niagen Bioscience serves consumers and commercial customers in the United States and international markets through online sales, retail and distribution channels.
About ODDITY Tech
ODDITY Tech Ltd. is a technology-driven consumer company that develops and operates digital-first beauty and wellness brands. Its portfolio includes IL MAKIAGE, which offers makeup and skincare products, and SpoiledChild, which focuses on beauty and wellness products. The company uses data analytics, artificial intelligence and other technology to support product development, personalized recommendations and online shopping. Its brands primarily sell directly to consumers through e-commerce platforms.
Receive News & Ratings for Niagen Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Niagen Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
